Positive Prelims for Lisata's Certepetide Combo with Chemo in Metastatic Pancreatic Cancer

 ASCEND comprises two dosing regimens of certepetide evaluated in two separate study arms enrolled sequentially

Positive signal in progression-free survival and objective response rate observed in certepetide-treated group compared to placebo-treated group

Cohort B data corroborate Cohort A data indicating certepetide has a treatment effect and an attractive safety profile

Full study data from both cohorts expected later this year

https://finviz.com/news/89409/positive-preliminary-cohort-b-results-from-the-agitg-led-ascend-trial-to-be-presented-at-esmo-gi-evaluating-lisatas-certepetide-in-combination-with-standard-of-care-chemotherapy-in-metastatic-pancreatic-cancer